Microcirculatory effects of angiotensin II inhibitors in patients with severe heart failure.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Ios Press Country of Publication: Netherlands NLM ID: 9709206 Publication Model: Print Cited Medium: Internet ISSN: 1875-8622 (Electronic) Linking ISSN: 13860291 NLM ISO Abbreviation: Clin Hemorheol Microcirc Subsets: MEDLINE
    • Publication Information:
      Publication: Amsterdam : Ios Press
      Original Publication: Amsterdam ; Washington, DC : IOS Press, c1997-
    • Subject Terms:
      Angiotensin II/*blood ; Angiotensin Receptor Antagonists/*therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/*therapeutic use ; Heart Failure/*blood ; Heart Failure/*drug therapy; Aged ; Captopril/therapeutic use ; Female ; Humans ; Male ; Microcirculation/drug effects ; Middle Aged ; Prospective Studies ; Renin-Angiotensin System/drug effects
    • Abstract:
      Context: The renin-angiotensin system is activated in patients with acute severe heart failure, and increased levels of angiotensin II could contribute to microcirculatory defects in these patients.
      Objective: To evaluate the microcirculatory effects of angiotensin II antagonists in critically ill patients with severe heart failure.
      Methods: After Ethics Committee approval and signed consent, we conducted a prospective observational study using sidestream darkfield (SDF) imaging to evaluate changes in the sublingual microcirculation of 25 adult patients with severe heart failure (ejection fraction < 40% or cardiac index < 2.5 L/min.m2) who received angiotensin inhibitors during their ICU stay. SDF images and global hemodynamic data were obtained immediately before and 4 h, 24 h, and 48 h after the first administration of the drug.
      Results: Already 4 h after administration, there was a significant improvement in the proportion of perfused small (<20 μm) vessels (PPV) (from 78 [72-84] to 89 [82-94]%, P < 0.05) and the microvascular flow index (MFI) (from 2.25 [1.95-2.50] to 2.80 [2.39-2.95] points, P < 0.05), which persisted over subsequent hours. Large vessel perfusion remained constant. There was no correlation between changes in the PPV and changes in the mean arterial pressure (R2 0.02, P = 0.50), cardiac output (R2 0.004, P = 0.85), or central or mixed venous oxygen saturation (R2 0.03, P = 0.53).
      Conclusions: In patients with severe heart failure, introduction of angiotensin antagonist therapy was associated with an early improvement in the microcirculation that persisted over subsequent hours. The microcirculatory effects were independent of global hemodynamic variables. The improvement in microcirculatory perfusion observed with angiotensin inhibitors in patients with severe heart failure may partially explain the beneficial clinical effects of this intervention in such patients.
    • Accession Number:
      0 (Angiotensin Receptor Antagonists)
      0 (Angiotensin-Converting Enzyme Inhibitors)
      11128-99-7 (Angiotensin II)
      9G64RSX1XD (Captopril)
    • Publication Date:
      Date Created: 20120815 Date Completed: 20140506 Latest Revision: 20130530
    • Publication Date:
      20221213
    • Accession Number:
      10.3233/CH-2012-1569
    • Accession Number:
      22890051